Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials (DISRUPT)
Diversity and Inclusion in Research Underpinning Trials
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Radhi Yagnik
- Phone Number: 212-659-5933
- Email: radhi.yagnik@mountsinai.org
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Care Center
-
The Bronx, New York, United States, 10461
- Albert Einstein College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients >21 years of age with invasive breast, lung or liver cancer, who face a treatment decision
- patients of doctors who have consented to participate
- able to give consent and speak either English or Spanish
- For provider recruitment, oncologists, and advanced practitioners caring for patients with breast, lung, liver cancer including medical and surgical oncologists, interventional radiologists & hepatologists will be eligible
Exclusion Criteria:
- Patients who are unable to give consent
- unable to understand English or Spanish
- lack of invasive breast/liver cancer
- those who do not face an imminent treatment decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Patient Participants
Patients with invasive breast, prostate or liver cancer, who face a treatment decision
|
Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
|
|
Active Comparator: Physician Participants
Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists & hepatologists
|
Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Clinical Trial Accrual
Time Frame: from start to the conclusion of recruitment to the clinical trial, average of 2 months
|
Change in rates of clinical trial accrual of the total population and BIPOC population.
|
from start to the conclusion of recruitment to the clinical trial, average of 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of physicians agree to usefulness of the match lists
Time Frame: at 6 months post intervention implementation
|
Number of physicians who find the match lists useful to inform decision-making and clinical trial participation.
|
at 6 months post intervention implementation
|
|
Patient Post-intervention Survey
Time Frame: 2 weeks post intervention implementation
|
Survey is not summed: there is no scoring or a scale for survey.
Questions will be looked at individually for statements related to patient level barriers that influenced CT discussions and offers.
Some answers are yes/no while others may multiple choices.
|
2 weeks post intervention implementation
|
|
Physician Post -intervention survey
Time Frame: at 6 months post intervention implementation
|
Survey is not summed: there is no scoring or a scale for survey.
Questions will be looked at individually for statements related to patient, physician, and system level barriers that influenced CT discussions and offers.
Some answers are yes/no while others may multiple choices.
|
at 6 months post intervention implementation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nina Bickell, Icahn School of Medicine at Mount Sinai
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Digestive System Neoplasms
- Digestive System Diseases
- Liver Diseases
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Prostatic Neoplasms
- Breast Neoplasms
- Liver Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- GCO 21-0012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.